Nile Therapeutics, Inc. Stock Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
05-13 | Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M | MT |
Sales 2024 * | 22.1M 30.11M | Sales 2025 * | 89.52M 122M | Capitalization | 168M 229M |
---|---|---|---|---|---|
Net income 2024 * | -38M -51.77M | Net income 2025 * | 4M 5.45M | EV / Sales 2024 * | 7.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.88 x |
P/E ratio 2024 * |
-4.54
x | P/E ratio 2025 * |
1,066
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
+0.96% | 22.27B | |
-12.64% | 22.22B | |
-4.64% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |